Index
RUT
P/E
-
EPS (ttm)
-11.68
Insider Own
31.33%
Shs Outstand
14.42M
Perf Week
17.58%
Market Cap
197.73M
Forward P/E
-
EPS next Y
-5.20
Insider Trans
68.06%
Shs Float
9.90M
Perf Month
22.41%
Enterprise Value
125.64M
PEG
-
EPS next Q
-1.34
Inst Own
58.88%
Perf Quarter
21.65%
Income
-113.50M
P/S
51.49
EPS this Y
56.56%
Inst Trans
28.60%
Perf Half Y
75.32%
Sales
3.84M
P/B
1.65
EPS next Y
4.17%
ROA
-58.83%
Perf YTD
71.16%
Book/sh
8.29
P/C
1.72
EPS next 5Y
25.06%
ROE
-87.78%
52W High
55.89 -75.47%
Perf Year
16.68%
Cash/sh
7.97
P/FCF
-
EPS past 3/5Y
62.00% 21.21%
ROIC
-71.06%
52W Low
5.20 163.43%
Perf 3Y
-18.88%
Dividend Est.
-
EV/EBITDA
-
Sales past 3/5Y
- -29.61%
Gross Margin
10.75%
Volatility
10.84% 9.74%
Perf 5Y
-97.28%
Dividend TTM
-
EV/Sales
32.72
EPS Y/Y TTM
-23.75%
Oper. Margin
-2154.03%
ATR (14)
1.12
Perf 10Y
-
Dividend Ex-Date
-
Quick Ratio
8.13
Sales Y/Y TTM
-20.31%
Profit Margin
-2954.14%
RSI (14)
61.61
Dividend Gr. 3/5Y
- -
Current Ratio
8.13
EPS Q/Q
32.11%
SMA20
15.19%
Beta
2.98
Payout
-
Debt/Eq
0.36
Sales Q/Q
-100.00%
SMA50
12.06%
Rel Volume
3.01
Prev Close
13.90
Employees
58
LT Debt/Eq
0.34
SMA200
-22.01%
Avg Volume
159.40K
Price
13.71
IPO
Oct 03, 2019
Option/Short
Yes / Yes
Trades
Volume
479,612
Change
-1.37%
Date
Action
Analyst
Rating Change
Price Target Change
May-18-26 Initiated Citigroup
Buy
$21
Mar-13-26 Upgrade Raymond James
Mkt Perform → Outperform
$23
Feb-17-26 Upgrade William Blair
Mkt Perform → Outperform
Jan-29-26 Upgrade Piper Sandler
Neutral → Overweight
$30
Jan-29-26 Upgrade H.C. Wainwright
Neutral → Buy
$20
Jan-29-26 Upgrade Chardan Capital Markets
Neutral → Buy
$15
Jan-28-26 Upgrade Oppenheimer
Perform → Outperform
$22
Jan-28-26 Upgrade Cantor Fitzgerald
Neutral → Overweight
$21
Nov-13-25 Downgrade William Blair
Outperform → Mkt Perform
Nov-13-25 Downgrade RBC Capital Mkts
Outperform → Sector Perform
$8
Nov-13-25 Downgrade Raymond James
Strong Buy → Mkt Perform
Nov-13-25 Downgrade Piper Sandler
Overweight → Neutral
$11
Nov-13-25 Downgrade H.C. Wainwright
Buy → Neutral
Nov-13-25 Downgrade Chardan Capital Markets
Buy → Neutral
$7
Nov-13-25 Downgrade Cantor Fitzgerald
Overweight → Neutral
Apr-29-25 Initiated Cantor Fitzgerald
Overweight
$74
Apr-16-25 Initiated Chardan Capital Markets
Buy
$25
Jan-10-25 Initiated Oppenheimer
Outperform
$155
Oct-21-24 Initiated Raymond James
Strong Buy
$153
Aug-14-24 Initiated William Blair
Outperform
$180
Show Previous Ratings
May-27-26 07:00AM
May-19-26 07:00AM
May-15-26 04:05PM
May-07-26 07:00AM
May-05-26 04:05PM
07:30AM
Loading…
Apr-16-26 07:30AM
Apr-10-26 04:05PM
Mar-12-26 04:05PM
Mar-10-26 06:09AM
Mar-09-26 07:30AM
Feb-26-26 12:15PM
Feb-25-26 04:05PM
Feb-02-26 09:53AM
Jan-30-26 07:35AM
03:08AM
09:35AM
Loading…
Jan-29-26 09:35AM
Jan-20-26 08:00AM
Jan-08-26 08:00AM
Nov-13-25 09:45AM
09:37AM
(Investor's Business Daily)
Nov-12-25 05:59PM
05:40PM
04:05PM
Sep-02-25 04:30PM
Aug-12-25 07:00AM
Jul-21-25 08:00AM
May-14-25 04:05PM
May-09-25 10:31AM
May-07-25 04:30PM
(GlobeNewswire)
-5.85%
+10.55%
Apr-01-25 07:30AM
07:30AM
Loading…
07:30AM
Mar-28-25 06:18PM
Mar-18-25 07:00AM
Mar-17-25 07:26AM
(Pharmaceutical Business Review)
Mar-14-25 08:00AM
Feb-26-25 08:00AM
Jan-13-25 08:00AM
Jan-07-25 08:00AM
Dec-10-24 08:00AM
Nov-21-24 04:01PM
07:30AM
Nov-14-24 08:00AM
Nov-12-24 04:05PM
(GlobeNewswire)
-11.37%
-15.55%
Nov-04-24 07:25AM
Oct-21-24 04:15PM
(Investor's Business Daily)
-5.22%
-7.70%
Oct-16-24 04:20PM
(Investor's Business Daily)
+93.66%
Sep-30-24 08:00AM
Sep-16-24 08:00AM
Sep-10-24 08:00AM
Aug-28-24 08:00AM
Aug-27-24 08:00AM
Aug-13-24 04:01PM
Jul-01-24 08:00AM
Jun-25-24 12:53PM
May-30-24 04:01PM
May-20-24 02:30PM
May-14-24 10:55PM
04:01PM
Apr-18-24 08:30AM
Apr-01-24 04:01PM
Mar-26-24 04:01PM
Feb-27-24 09:55AM
08:00AM
Feb-09-24 09:55AM
Jan-18-24 08:00AM
Jan-04-24 08:00AM
Dec-07-23 08:00AM
Nov-28-23 08:00AM
Nov-03-23 03:31PM
12:19PM
Aug-10-23 04:01PM
Jul-17-23 11:59AM
Jul-14-23 11:22AM
06:30AM
May-12-23 04:01PM
Mar-10-23 07:30AM
Feb-27-23 07:30AM
Feb-13-23 01:55PM
(American City Business Journals)
-80.54%
11:17AM
08:05AM
Dec-19-22 07:30AM
Dec-15-22 07:30AM
Nov-17-22 07:30AM
Nov-08-22 04:05PM
Oct-12-22 07:30AM
Aug-30-22 07:30AM
Aug-09-22 04:05PM
(Business Wire)
-11.11%
+9.00%
Jun-24-22 09:03AM
May-25-22 12:00PM
May-18-22 07:30AM
May-04-22 04:30PM
Apr-22-22 07:30AM
Apr-08-22 05:00PM
Mar-15-22 07:30AM
Mar-10-22 06:35PM
Feb-28-22 07:30AM
Jan-14-22 05:43AM
Jan-04-22 07:30AM
Dec-28-21 02:38AM
Dec-09-21 01:18PM
Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company was founded by Nessan Bermingham, Jean-Francois B. Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.
Ph.D. Dr. Ram Aiyar MBA
Chief Scientific Officer Dr. Loic Vincent Ph.D.
Pharm.D. Dr. Jeffrey M. Cerio J.D.
Co-Founder & Advisor Dr. Andrew Fraley Ph.D.
Co-Founder & Advisor Dr. Joshua Rosenthal Ph.D.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Atlas Venture Opportunity Fund Shareholder Jun 23 '26 Proposed Sale 13.90 17,426 242,221 Jun 23 06:12 PM Atlas Venture Fund XI, L.P. Shareholder Jun 23 '26 Proposed Sale 13.90 101,579 1,411,948 Jun 23 06:12 PM Atlas Venture Fund XI, L.P. Shareholder Jun 22 '26 Proposed Sale 12.99 21,339 277,194 Jun 22 05:32 PM Atlas Venture Opportunity Fund Shareholder Jun 22 '26 Proposed Sale 12.99 3,661 47,556 Jun 22 05:30 PM Chappell Todd Chief Operating Officer Jun 16 '26 Sale 10.83 3,168 34,309 16,964 Jun 17 04:14 PM Vincent Loic A Chief Scientific Officer Jun 16 '26 Sale 10.83 3,418 37,017 18,297 Jun 17 04:11 PM Cerio Jeffrey General Counsel Jun 16 '26 Sale 10.83 6,609 71,575 35,293 Jun 17 04:08 PM Dolan Oliver Senior Vice President, Finance Jun 16 '26 Sale 10.83 3,383 36,638 18,099 Jun 17 04:05 PM Vincent Loic A Officer Jun 16 '26 Proposed Sale 10.83 3,418 37,017 Jun 16 04:48 PM Cerio Jeffrey Officer Jun 16 '26 Proposed Sale 10.83 6,609 71,576 Jun 16 04:44 PM Dolan Oliver Officer Jun 16 '26 Proposed Sale 10.83 3,383 36,638 Jun 16 04:44 PM Chappell Todd Officer Jun 16 '26 Proposed Sale 10.83 3,168 34,310 Jun 16 04:42 PM Aiyar Ram President and CEO May 29 '26 Sale 12.98 15,152 196,673 74,848 Jun 02 07:00 AM FORMELA JEAN FRANCOIS Director May 28 '26 Sale 13.95 2,860 39,897 194,655 Jun 01 05:35 PM Aiyar Ram Officer May 29 '26 Proposed Sale 12.98 15,152 196,676 May 29 03:09 PM Lynx1 Capital Management LP 10% Owner Mar 31 '26 Buy 10.60 520 5,512 1,538,296 Apr 02 12:00 PM Yang Rick 10% Owner Mar 10 '26 Buy 11.11 207,100 2,300,881 1,297,893 Mar 12 08:15 PM SANDELL SCOTT D 10% Owner Mar 10 '26 Buy 11.11 207,100 2,300,881 1,297,893 Mar 12 08:15 PM New Enterprise Associates 17, 10% Owner Mar 10 '26 Buy 11.11 207,100 2,300,881 1,297,893 Mar 12 08:15 PM Chang Carmen 10% Owner Mar 10 '26 Buy 11.11 207,100 2,300,881 1,297,893 Mar 12 08:15 PM BASKETT FOREST 10% Owner Mar 10 '26 Buy 11.11 207,100 2,300,881 1,297,893 Mar 12 08:15 PM Mathers Edward T 10% Owner Mar 10 '26 Buy 11.11 207,100 2,300,881 1,297,893 Mar 12 08:15 PM Makhzoumi Mohamad 10% Owner Mar 10 '26 Buy 11.11 207,100 2,300,881 1,297,893 Mar 12 08:15 PM Walker Paul Edward 10% Owner Mar 10 '26 Buy 11.11 207,100 2,300,881 1,297,893 Mar 12 08:15 PM Florence Anthony A. Jr. 10% Owner Mar 10 '26 Buy 11.11 207,100 2,300,881 1,297,893 Mar 12 08:15 PM
